
Aurobindo gets Form 483 scolding from FDA at North Carolina inhaler plant
Aurobindo's manufacturing operations have once again landed the Indian drugmaker in hot water with the U.S. FDA. Aurobindo's subsidiary Aurolife Pharma received a Form 483 from the FDA outlining 11 observations at a U.S. production plant, the …